Adam C. Bell, PhD, RAC has a strong background in regulatory affairs and medical research. Adam C. is currently the Vice President of Translational Medicine and Regulatory Affairs at Neuraly, Inc. Since joining in 2018, they have been leading the company's efforts in developing and implementing regulatory strategies for their medical products.
Prior to their current role, Adam worked as the Manager of Regulatory Affairs and Medical Experts Office at ICON Government and Public Health Solutions from 2016 to 2018. In this position, they oversaw regulatory affairs initiatives and managed a team of medical experts.
From 2011 to 2016, Adam served as a Regulatory Affairs Scientist at Clinical Research Management, Inc. (ClinicalRM). During their time there, they focused on regulatory compliance and scientific support for projects at Walter Reed, NMRC, and USAMMDA.
Before joining ClinicalRM, Adam worked at Teva Pharmaceuticals as the Director of Medical and Scientific Affairs from 2008 to 2010. In this role, they provided project leadership for clinical development and regulatory affairs. Adam C. also supervised clinical operations and played a key role in global clinical development projects.
From 2006 to 2008, Adam was the Associate Director of Lead Identification and Product Planning at CoGenesys, Inc. Here, they supervised a team of scientists and led pre-clinical and clinical development programs. Adam C. also provided oversight for regulatory affairs, clinical operations, and statistics.
Earlier in their career, Adam worked as a Senior Scientist at Human Genome Sciences from 2000 to 2006. Adam C. actively participated in lab work and project teams, contributing to the discovery and patenting of therapeutic proteins and antibody targets.
Adam started their career as a Post-Doc at NIH from 1994 to 2000. During this time, they made significant contributions to the understanding of the hemoglobin gene system and discovered a regulatory protein responsible for genetic elements called insulators. Adam C. also uncovered the role of DNA methylation in controlling the function of the insulator protein, which explained how genes were differentially expressed in organisms.
Overall, Adam C. Bell, PhD, RAC has a diverse and extensive work experience in regulatory affairs, clinical development, and medical research across various organizations.
Adam C. Bell, PhD, RAC, completed their Bachelor of Science degree in Biology at Stony Brook University from 1984 to 1988. Following this, they pursued higher education and obtained their Ph.D. in Biology from the University at Buffalo, where they studied from 1988 to 1994.
February, 2018 - present